Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer

被引:11
作者
Krawczyk, Pawel Adam [1 ]
Kowalski, Dariusz M. [2 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland
[2] Maria Sklodowska Curie Inst, Ctr Oncol, Dept Lung Canc & Thorac, Roentgena 5, PL-02640 Warsaw, Poland
来源
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2014年 / 18卷 / 01期
关键词
cetuximab; panitumumab; metastatic colorectal cancer; mCRC; EGFR; ADCC;
D O I
10.5114/wo.2013.38566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Efficacy of monoclonal anti-EGFR antibody (cetuximab, panitumumab) in combination with chemotherapy and alone has been demonstrated in clinical trials in patients withmCRC. Both drugs block signaling EGFR pathway in malignant cells (blocking ligand binding and EGFR dimerization). Receive treatment responses with anti-EGFR agents is possible only in a selected group of patients with mCRC. Successful treatment with cetuximab and panitumabem is possible almost exclusively in patients without RAS mutations. Research of predictive value of EGFR gene copy number, PI3KCA gene mutations, P53 and PTEN and EGFR their ligands concentrations is ongoing. Due to the different molecular structure (IgG1 chimericmonoclonal antibody) and panitumumab (IgG2 humanized antibody) it is possible an additional characteristic of the mechanism of action of cetuximab (antibody dependent cellular cytotoxicity). Therefore predictor cetuximab therapymay be the presence of different polymorphic forms of the genes for receptor immunoglobulin Fc fragments: Fc gamma RIIa and Fc gamma RIII subclasses.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 74 条
[1]   Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].
Adams, Richard A. ;
Meade, Angela M. ;
Seymour, Matthew T. ;
Wilson, Richard H. ;
Madi, Ayman ;
Fisher, David ;
Kenny, Sarah L. ;
Kay, Edward ;
Hodgkinson, Elizabeth ;
Pope, Malcolm ;
Rogers, Penny ;
Wasan, Harpreet ;
Falk, Stephen ;
Gollins, Simon ;
Hickish, Tamas ;
Bessell, Eric M. ;
Propper, David ;
Kennedy, M. John ;
Kaplan, Richard ;
Maughan, Timothy S. .
LANCET ONCOLOGY, 2011, 12 (07) :642-653
[2]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[3]  
[Anonymous], J CLIN ONCOL
[4]   Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer [J].
Baker, J. B. ;
Dutta, D. ;
Watson, D. ;
Maddala, T. ;
Munneke, B. M. ;
Shak, S. ;
Rowinsky, E. K. ;
Xu, L-A ;
Harbison, C. T. ;
Clark, E. A. ;
Mauro, D. J. ;
Khambata-Ford, S. .
BRITISH JOURNAL OF CANCER, 2011, 104 (03) :488-495
[5]  
Barriere J, 2009, J CLIN ONCOL, V27
[6]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[7]   Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].
Bibeau, Frederic ;
Lopez-Crapez, Evelyne ;
Di Fiore, Frederic ;
Thezenas, Simon ;
Ychou, Marc ;
Blanchard, France ;
Lamy, Aude ;
Penault-Llorca, Frederique ;
Frebourg, Thierry ;
Michel, Pierre ;
Sabourin, Jean-Christophe ;
Boissiere-Michot, Florence .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129
[8]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[9]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[10]   KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].
De Roock, W. ;
Piessevaux, H. ;
De Schutter, J. ;
Janssens, M. ;
De Hertogh, G. ;
Personeni, N. ;
Biesmans, B. ;
Van Laethem, J. -L. ;
Peeters, M. ;
Humblet, Y. ;
Van Cutsem, E. ;
Tejpar, S. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515